Clinical Trials Browser

Phase 1 × OTHER × durvalumab × Clear all

NCT04605731 2026-04-20

Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer

Phase 1 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT07107750 2026-04-03

Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer

Phase 1 Recruiting

Gastrointestinal

Biliary Tract Neoplasms

NCT03923270 2026-04-01

Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

Phase 1 Active not recruiting

Lung Neoplasms, Small Cell Lung Carcinoma

NCT02997332 2026-03-23

MEDINDUCTION

Phase 1 Terminated

Head and Neck Neoplasms

NCT04387084 2026-03-23

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

Phase 1 Active not recruiting

Skin Neoplasms

NCT06083454 2026-03-13

Ascorbate With Durvalumab in Non-Small Cell Lung Cancer (NSCLC)

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung

NCT05733689 2026-03-10

Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)

Phase 1 Recruiting

Gastrointestinal

Gastroesophageal Adenocarcinoma

NCT06963346 2026-03-09

Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents

Phase 1 Suspended

Urinary Bladder Neoplasms

NCT05403723 2026-02-19

Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC

Phase 1 Suspended

Lung Neoplasms, Small Cell Lung Carcinoma

NCT05443971 2026-02-06

Durvalumab and Grid Therapy for Non-small Cell Lung Cancer in Progression During or After Treatment With PACIFIC Regimen

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05154994 2026-01-27

RESOLVE

Phase 1 Active not recruiting

Carcinoma, Transitional Cell

NCT05155189 2026-01-21

A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma

Phase 1 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT06124118 2026-01-08

NOVOCURE

Phase 1 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06218511 2025-12-22

A Phase I Trial of IMA970A Plus Montanide in Combination With Durvalumab (Anti-PD-L1)

Phase 1 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT04550104 2025-12-19

CONCORDE

Phase 1 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06546969 2025-12-10

Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer

Phase 1 Recruiting

Gastrointestinal

Biliary Tract Neoplasms, Cholangiocarcinoma

NCT03257761 2025-12-05

Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer

Phase 1 Active not recruiting

Gastrointestinal

Gallbladder Neoplasms, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Cholangiocarcinoma

NCT03381183 2025-12-05

IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma

Phase 1 Completed

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT06564623 2025-12-05

Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)

Phase 1 Recruiting

Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Biliary Tract Neoplasms, Carcinoma

NCT02639026 2025-11-25

Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers

Phase 1 Completed

BreastDermatologicGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms

NCT04895579 2025-11-18

LCD

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung

NCT06058663 2025-10-20

Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma

Phase 1 Recruiting

Gastrointestinal

Cholangiocarcinoma

NCT02826434 2025-10-01

Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer

Phase 1 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03019003 2025-09-16

Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients

Phase 1 Completed

13 enrolled 12 charts

Head and Neck Neoplasms

NCT03085225 2025-09-04

TRAMUNE

Phase 1 Completed

40 enrolled 23 charts

GynecologicSarcoma

Ovarian Neoplasms, Sarcoma

NCT05701488 2025-09-02

SIRT With Tremelimumab and Durvalumab for Resectable HCC

Phase 1 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT03635164 2025-06-27

Radiotherapy With Durvalumab Prior to Surgical Resection for HPV Negative Squamous Cell Carcinoma

Phase 1 Completed

Squamous Cell Carcinoma of Head and Neck

NCT05136846 2025-06-04

Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer

Phase 1 Recruiting

Lung Neoplasms

NCT03277482 2025-05-31

Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer

Phase 1 Terminated

Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

NCT05358691 2025-04-16

A Trial of AN0025 With Chemoradiation Therapy in Stage III NSCLC Participants

Phase 1 Withdrawn

Lung Neoplasms

NCT04108481 2025-03-28

iRE-C

Phase 1 Terminated

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT05911308 2025-03-21

Abequolixron (RGX-104) and Durvalumab in Lung Cancer

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung

NCT06710223 2025-02-11

Cryoablation and Arterial Infusion of SD-101 in Combination with Durvalumab and Tremelimumab

Phase 1 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT03802747 2024-12-09

Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases

Phase 1 Withdrawn

Gastrointestinal

Colorectal Neoplasms

NCT04287894 2024-11-06

Induction

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung

NCT02754856 2024-10-09

Tremelimumab and Durvalumab in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery

Phase 1 Completed

24 enrolled 12 charts

Gastrointestinal

Colorectal Neoplasms

NCT04348292 2024-08-22

Sirolimus and Durvalumab for the Treatment of Stage I-IIIA Non-small Cell Lung Cancer

Phase 1 Terminated

3 enrolled 7 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03199040 2024-05-28

Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy

Phase 1 Terminated

18 enrolled 9 charts

Triple Negative Breast Neoplasms

NCT02762006 2024-03-18

Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma

Phase 1 Completed

Carcinoma, Renal Cell, Kidney Neoplasms

NCT06304597 2024-03-12

PREDICT

Phase 1 Unknown

Gastrointestinal

Locally Advanced Rectal Carcinoma

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT05848843 2024-01-23

A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations

Phase 1 Withdrawn

Lung Neoplasms

NCT02793466 2023-09-22

Durvalumab in Pediatric and Adolescent Patients

Phase 1 Completed

Lymphoma, Central Nervous System Neoplasms

NCT03452332 2023-09-13

Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers

Phase 1 Completed

Uterine Cervical Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms

NCT03963414 2023-08-28

A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC

Phase 1 Terminated

Small Cell Lung Carcinoma

NCT03275597 2023-05-15

Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung

NCT03732664 2023-03-24

ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer

Phase 1 Completed

High-Risk Resectable NSCLC

NCT01975831 2022-10-12

A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab

Phase 1 Completed

104 enrolled 23 charts

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

NCT02716805 2022-10-12

Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant

Phase 1 Terminated

6 enrolled 11 charts

Diabetes Mellitus, Insulin-Dependent, 12, Multiple Myeloma

NCT03773666 2022-09-13

A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2)

Phase 1 Completed

Urinary Bladder Neoplasms